Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome (CLEAR ACS) Study

NCT05263778 is registered in ClinicalTrials.gov with Kaiser Permanente as lead sponsor.

NCT NCT05263778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05263778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome (CLEAR ACS) Study
Lead sponsor
Kaiser Permanente
Phase
Phase 4
Overall status
Unknown status
Start date
March 31, 2022
Completion date
December 31, 2023
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular diseases, nstemi, stemi